Intracameral bevacizumab administered for non-small cell lung cancer metastasis to iris

  • Jonathan C. Schell The Eye Institute, Department of Ophthalmology, Medical College of Wisconsin, United States.
  • Steven B. Koenig The Eye Institute, Department of Ophthalmology, Medical College of Wisconsin, United States.
  • Kenneth Bastin Radiation Oncology Associates Ltd., St Luke’s Medical Center, Milwaukee, Wisconsin, United States.
  • William J. Wirostko | wirostko@mcw.edu The Eye Institute, Department of Ophthalmology, Medical College of Wisconsin, United States.

Abstract

Ocular iris metastasis from lung cancer is uncommon. We report a patient with metastatic non-small cell lung cancer who was found to have a metastatic lesion to the iris. Local therapy for pain control and vision loss was administered with intracameral bevacizumab. Complete resolution of pain, improvement in vision, and near complete resolution of iris tumor were seen within two months. No ocular toxicity to anterior segment structures was detectable on corneal pachymetry and corneal specular microscopy. This is the first case report demonstrating safety and efficacy of intracameral bevacizumab for iris metastasis from non-small cell lung cancer.

Google Scholar

Google Scholar

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biography

William J. Wirostko, The Eye Institute, Department of Ophthalmology, Medical College of Wisconsin

Vitreoretinal Section, Dept. of Ophthalmology

Associate Professor of Ophthalmology

Published
2011-05-30
Info
Issue
Section
Case Reports
Keywords:
bevacizumab, non-small cell lung cancer, iris metastasis.
Statistics
  • Abstract views: 1463

  • PDF: 168
  • HTML: 213
How to Cite
Schell, J. C., Koenig, S. B., Bastin, K., & Wirostko, W. J. (2011). Intracameral bevacizumab administered for non-small cell lung cancer metastasis to iris. Clinics and Practice, 1(2), e39. https://doi.org/10.4081/cp.2011.e39